Back to Search Start Over

Efficacy of Catheter Ablation for Atrial Arrhythmias in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy—A Multicenter Study

Authors :
Alessio Gasperetti
Cynthia A. James
Liang Chen
Niklas Schenker
Michela Casella
Shinwan Kany
Shibu Mathew
Paolo Compagnucci
Andreas Müssigbrodt
Henrik K. Jensen
Anneli Svensson
Sarah Costa
Giovanni B. Forleo
Pyotr G. Platonov
Claudio Tondo
Jiang-Ping Song
Antonio Dello Russo
Frank Ruschitzka
Corinna Brunckhorst
Hugh Calkins
Firat Duru
Ardan M. Saguner
Source :
Journal of Clinical Medicine, Vol 10, Iss 21, p 4962 (2021)
Publication Year :
2021
Publisher :
MDPI AG, 2021.

Abstract

Background: Atrial arrhythmias are present in up to 20% of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). Catheter ablation (CA) is an effective treatment for atrial arrhythmias in the general population. Data regarding CA for atrial arrhythmias in ARVC are scarce. Objective: To assess the safety and efficacy of CA for atrial arrhythmias in patients with ARVC. Methods: In this international collaborative effort, all patients with a definite diagnosis of ARVC undergoing CA for atrial fibrillation (AF), focal atrial tachycardia (AT), or cavotricuspid isthmus (CTI)-dependent atrial flutter (AFl) were extracted from twelve ARVC registries. Demographic, periprocedural, and long-term arrhythmic outcome data were collected. Results: Thirty-seven patients were enrolled in the study (age 50.2 ± 16.6 years, male 84%, CHA2DS2VASc 1 (1,2), HAS-BLED 0 (0–2)). The arrhythmia leading to CA was AF in 23 (62%), focal left AT in 5 (14%), and CTI-dependent AFl in 9 (24%). Acute procedural success was achieved in all procedures but one (n = 1 focal left AT; 97% acute success). The median follow-up period was 27 (13–67) months, and 96%, 74%, and 61% of patients undergoing AF ablation were free from any atrial arrhythmia recurrence after a single procedure at 6 months, 12 months, and last follow-up, respectively. After focal AT ablation, freedom from atrial arrhythmia recurrence was 80%, 80%, and 60% at 6 months, 12 months, and last follow-up, respectively. All patients undergoing CTI ablation were free from atrial arrhythmia recurrences at 6 months, with 89% single-procedural arrhythmic freedom at last follow-up. One major complication (2.7%; PV stenosis requiring PV stenting) occurred. Conclusions: CA is safe and effective in managing atrial arrhythmias in patients with ARVC, with success rates comparable to the general population.

Details

Language :
English
ISSN :
20770383
Volume :
10
Issue :
21
Database :
Directory of Open Access Journals
Journal :
Journal of Clinical Medicine
Publication Type :
Academic Journal
Accession number :
edsdoj.3f4edaafc7c1464cbc4537fc1787ff13
Document Type :
article
Full Text :
https://doi.org/10.3390/jcm10214962